WHEN YOU THINK OF A BUILD-UP OF PLAQUE IN YOUR BODY, YOU MIGHT THINK OF YOUR HEART... BUT BUILD-UPS IN OTHER PLACES CAN BE DANGEROUS TOO.
NOW, DOCTORS ARE TESTING A NEW TECH TOOL TO HELP THEM REMOVE THE PROBLEM WITHOUT REMOVING LIMBS.
YOU'RE LOOKING AT A VIAL FULL OF PLAQUE.
SIMILAR TO A BLOCKAGE YOU'D FIND IN A CLOGGED HEART DETROIT MEDICAL CENTER DOCTOR MAHIR ELDER TOOK IT OUT OF AN ARTERY IN A PATIENT'S LEG. THE RESULT OF PERIPHERAL ARTERIAL DISEASE.
"This is a very critical disease that is obstructing blood supply to the feet."
BETWEEN EIGHT AND TEN-MILLION PEOPLE IN THE U-S HAVE P-A-D. EVERY YEAR IT COSTS 200-THOUSAND THEIR LIMBS.
"Oh, I was fearful of amputation."
JOE KALISH HAS BEEN STRUGGLING WITH P-A-D FOR MORE THAN A DECADE.
"I'd walk from the bedroom to the living room and I had to sit down. My legs would just ache."
BUT RECENTLY HE TOOK PART IN THE CONNECT-TWO TRIAL. LED IN PART BY DOCTOR ELDER. IT'S TESTING THE OCELOT. A DEVICE GIVING DOCTORS A NEW VIEW INSIDE VESSELS.
"It uses ultrasound technology as it swipes in a 360 degree motion and subsequently giving us a three dimensional image. It is a game changer because now we can identify the vessel anatomy while we're inside the vessel."
THE DOCTOR SAYS THESE IMAGES HELP HIM STAY IN THE MIDDLE OF THE VESSEL WHILE HE SHAVES AWAY THE BUILD UP OR BLASTS IT WITH A LASER. THE MORE CENTER HE IS THE BETTER CHANCES IT WON'T CLOSE UP AGAIN. HERE'S A PATIENT'S LEG BEFORE..AND AFTER TREATMENT ASSISTED BY THE OCELOT.
"The trial has shown that the patients are getting better results right away."
AS FOR JOE, HIS CIRCULATION'S BACK AND HIS PAIN IS ALMOST COMPLETELY GONE.
"It's great. It's like a child doing his first steps all over again That's how great it makes me feel."
THE CONNECT TWO TRIAL TESTING THE OCELOT IS NOW CLOSED.
BUT, WHILE THE TECHNOLOGY AWAITS F-D-A APPROVAL HOSPITALS THAT TOOK PART IN THE STUDY ARE ALLOWED TO CONTINUE TREATING PATIENTS WITH THE OCELOT.
GO TO email@example.com TO FIND THE HOSPITAL CLOSEST TO YOU.
Copyright 2016 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.